NRG Oncology February 2019 Semiannual Meeting
Phoenix Convention Center

PRESENTATIONS

NRG Oncology Phase II Randomized Trial of nivolumab with or without Ipilimumab in patients with persistent or recurrent ovarian cancer.

**Presenter:** Robert Burger, MD  
**Discussant:** Sarah Temkin, MD

Preservation of neurocognitive function (NCF) with hippocampal avoidance during whole-brain radiotherapy (WBRT) for brain metastases: preliminary results of phase III trial NRG Oncology CC001.

**Presenter:** Vinai Gondi, MD  
**Discussant:** Paul Sperduto, MD


**Presenter:** Andy Trotti, MD, PhD  
**Discussant:** Stuart Wong, MD

NRG Oncology Phase II Randomized Trial of nivolumab with or without Ipilimumab in patients with persistent or recurrent ovarian cancer.

**Presenter:** Robert Burger, MD  
**Discussant:** Sarah Temkin, MD

Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: the NRG Oncology/RTOG 0534 SPPORT Trial.

**Presenter:** Alan Pollack, MD  
**Discussant:** William Hall, MD

Post-resection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: analysis of NRG Oncology RTOG trial 9704

**Presenter:** William Regine, MD  
**Discussant:** Richard Tuli, MD

Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, 1, or II breast cancer.

**Presenter:** Frank, Vicini, MD  
**Discussant:** Atif Khan, MD

Register for the semiannual meeting on the NRG Oncology website